Week in Review: Beta-blockers inferior to other therapies | Processed meat & CVD risk | FDA approves Harmony TPV

The authors tracked outcomes from more than 386,000 patients treated from 2001 to 2018, sharing their findings in Hypertension.

The study's authors tracked the health of more than 134,000 individuals from 21 countries for nearly a decade. 

The solution’s approval was based on 30-day and six-month data from a clinical study focused on mortality and hemodynamic function.

The analysis, published in Circulation: Cardiovascular Quality and Outcomes, included data from more than 87,000 Medicare patients. 

The findings, published in JAMA Cardiology, confirm that dapagliflozin is a safe, effective treatment option for patients with heart failure with reduced ejection fraction.

The injection, being marketed as Zegalogue, will be made available in an auto injector or a prefilled syringe.

The new AI tool can be used alongside GE Healthcare’s full line of Venue ultrasound systems, including the new Venue Fit. 

Itchhaporia, an interventional cardiologist, most recently served as the ACC's vice president. 

The ongoing saga continues. Both Germany and Canada have now limited the use of the AstraZeneca vaccine among younger adults. 

One important detail, however, was that acute kidney injury was more common for kidney transplant recipients. The researchers listed numerous potential explanations for this trend.